G

Genomed SA
WSE:GEN

Watchlist Manager
Genomed SA
WSE:GEN
Watchlist
Price: 26.2 PLN 4.8% Market Closed
Market Cap: 34.6m PLN
Have any thoughts about
Genomed SA?
Write Note

Genomed SA
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genomed SA
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
G
Genomed SA
WSE:GEN
Depreciation & Amortization
zł618.6k
CAGR 3-Years
-4%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
M
Mabion SA
WSE:MAB
Depreciation & Amortization
zł8.2m
CAGR 3-Years
-2%
CAGR 5-Years
-6%
CAGR 10-Years
22%
R
Read Gene SA
WSE:RDG
Depreciation & Amortization
zł462k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Depreciation & Amortization
zł35.8m
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
27%
U
Urteste SA
WSE:URT
Depreciation & Amortization
zł776k
CAGR 3-Years
273%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Depreciation & Amortization
zł6.6m
CAGR 3-Years
4%
CAGR 5-Years
-28%
CAGR 10-Years
14%
No Stocks Found

Genomed SA
Glance View

Market Cap
34.6m PLN
Industry
Biotechnology

Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

GEN Intrinsic Value
25.37 PLN
Overvaluation 3%
Intrinsic Value
Price
G

See Also

What is Genomed SA's Depreciation & Amortization?
Depreciation & Amortization
618.6k PLN

Based on the financial report for Dec 31, 2023, Genomed SA's Depreciation & Amortization amounts to 618.6k PLN.

What is Genomed SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-8%

Over the last year, the Depreciation & Amortization growth was -14%. The average annual Depreciation & Amortization growth rates for Genomed SA have been -4% over the past three years , -8% over the past five years .

Back to Top